Lab assay finds stronger CB1 activation for some longer-chain HHC derivatives
Pharmacological characterization of emerging hexahydrocannabinol-derived semi-synthetic cannabinoids at the cannabinoid type 1 receptor using a β-arrestin2 recruitment assay.
AI Summary
This laboratory study tested 14 HHC-derived semi-synthetic cannabinoids, including different side-chain lengths and esterified compounds, in a cell-based β-arrestin2 recruitment assay to measure activation of the CB1 receptor. The assay measured each compound’s potency and efficacy; it is a laboratory proxy for activity, not a test of effects or abuse potential in people.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More Endocannabinoid research papers you might find interesting.
Meta-analysis finds shared endocannabinoid gene changes across myopathies
Small biomarker analysis finds no significant changes after 10 HBOT sessions
Rat study finds mixed behavioral and biological effects of WIN under chronic…
Explore More Research
Stay informed about the latest cannabis science.